Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Hepatitis C Virus

Interventions

DRUG

PF-04878691 3mg

Oral solution, 3mg, twice weekly, 2 weeks

DRUG

PF-04878691 6mg

Oral solution, 6mg, twice weekly, 2 weeks

DRUG

PF-04878691 9mg

Oral solution, 9mg, twice weekly, 2 weeks

Trial Locations (1)

Pfizer Investigational Site, New Haven